(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
25 January 2007 (25.01.2007)

PCT

(10) International Publication Number
WO 2007/010285 A3

(51) International Patent Classification:
*C12N 9/88* (2006.01) *G01N 33/00* (2006.01)

(21) International Application Number:
PCT/GB2006/002750

(22) International Filing Date: 21 July 2006 (21.07.2006)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/701,122 21 July 2005 (21.07.2005) US

(71) Applicant *(for all designated States except US)*: **ASTEX THERAPEUTICS LIMITED** [GB/GB]; 436 Cambridge Science Park, Milton Road, Cambridge Cambridgeshire CB4 0QA (GB).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **SAALAU-BETHELL, Susanne, Maria** [GB/GB]; Astex Therapeutics Limited, 436 Cambridge Science Park, Milton Road, Cambridge Cambridgeshire CB4 0QA (GB). **CLEASBY, Anne** [GB/GB]; Astex Therapeutics Limited, 436 Cambridge Science Park, Milton Road, Cambridge Cambridgeshire CB4 0QA (GB). **SAMBROOK, Tracey, Ann** [GB/GB]; Cambridge Cambridgeshire CB4 9HE (GB). **COYLE, Joseph** [GB/GB]; Astex Therapeutics Limited, 436 Cambridge Science Park, Milton Road, Cambridge Cambridgeshire CB4 0QA (GB). **VINKOVIC, Mladen** [HR/GB]; Astex Therapeutics Limited, 436 Cambridge Science Park, Milton Road, Cambridge Cambridgeshire CB4 0QA (GB).

(74) Agents: **BRASNETT, Adrian** et al.; Mewburn Ellis LLP, York House, 23 Kingsway, London Greater London WC2B 6HP (GB).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

(88) Date of publication of the international search report:
18 May 2007

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: CRYSTAL STRUCTURE OF HUMAN SOLUBLE ADENYLATE CYCLASE

(57) Abstract: The invention provides the crystal structure of the solAC catalytic domain. The structure is set out in Tables 1 to 5. The structure may be used in to model the interaction of ligands such as pharmaceutical compounds with this protein, and to determine the structure of related adenylate cyclase molecules.

WO 2007/010285 A3